

AMENDMENT TO THE RULES COMMITTEE PRINT
FOR H.R. 4909
OFFERED BY MR. CARTER OF TEXAS

At the end of subtitle C of title VII, add the following new section:

1 **SEC. 7___ . USE OF MEFLOQUINE FOR MALARIA.**

2 (a) MEFLOQUINE.—In providing health care to mem-
3 bers of the Armed Forces, the Secretary of Defense shall
4 require—

5 (1) that the use of mefloquine for the prophylaxis of malaria be limited to members with intolerance or contraindications to other chemoprophylaxis;

6 (2) that mefloquine be prescribed by a licensed
7 medical provider on an individual basis, and

8 (3) that members prescribed mefloquine for malaria prophylaxis be counseled by the medical provider about the potential side effects of the drug and be provided the Food and Drug Administration-required patient information handouts.

9 (b) PROCESS AND REVIEW.—

10 (1) PROCESS.—Not later than 180 days after
11 the date of the enactment of this Act, in providing
12 health care to members of the Armed Forces, the
13
14
15
16
17
18

1 Secretary shall develop a standardized process to
2 document the screening for contraindications and
3 patient education, including a prior authorization
4 form, to be used by all medical providers prescribing
5 mefloquine for malaria prophylaxis.

6 (2) ANNUAL REVIEW.—The Secretary shall con-
7 duct an annual review of each mefloquine prescrip-
8 tion at all military medical treatment facilities to
9 evaluate the documentation of the assessment for
10 contraindications, justification for not using other
11 chemoprophylaxis, and patient education for the safe
12 use of mefloquine and its side effects.

13 (c) ADVERSE HEALTH EFFECTS OF MEFLOQUINE.—
14 The Secretary of Defense shall expand the missions of the
15 Hearing Center of Excellence, the Vision Center of Excel-
16 lence, the Defense Centers of Excellence for Psychological
17 Health and Traumatic Brain Injury (including the De-
18 ployment Health Clinical Center), and the Center for De-
19 ployment Health Research to include, as appropriate, im-
20 proving the clinical evaluation, diagnosis, management,
21 and epidemiological study of adverse health effects among
22 members of the Armed Forces following exposure to
23 mefloquine.

